CD2

Summary

CD2 (CD2 molecule, HGNC:1639) is a protein-coding gene on chromosome 1p13.1, encoding T-cell surface antigen CD2 (P06729). CD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types.

The protein encoded by this gene is a surface antigen found on all peripheral blood T-cells. The encoded protein interacts with LFA3 (CD58) on antigen presenting cells to optimize immune recognition. A locus control region (LCR) has been found in the 3’ flanking sequence of this gene.

Source: NCBI Gene 914 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 67 total
• GTEx eGene: eQTL in 3 tissues, sQTL in 0 (q < 0.05)
• Drug target: yes — 2 curated mechanism-of-action drugs
• Approved drugs (ChEMBL mechanism of action): 1 — Alefacept
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.14 (unconstrained)
• MANE Select transcript: NM_001767
• Interaction hub: 2,308 STRING partners (top 5% of genes corpus-wide)
• Notable: 67 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1639
Approved symbol	CD2
Name	CD2 molecule
Location	1p13.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000116824
Ensembl biotype	protein_coding
OMIM	186990
Entrez	914

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 7 protein_coding, 1 nonsense_mediated_decay

MANE Select: ENST00000369478

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 1

ENST00000369478, ENST00000369477, ENST00000851329, ENST00000851330, ENST00000851331, ENST00000987291, ENST00001092601, ENST00001141137

RefSeq mRNA: 2 — MANE Select: NM_001767 NM_001328609, NM_001767

CCDS: CCDS889

Canonical transcript exons

ENST00000369478 — 5 exons

Exon	Start	End
ENSE00000785006	116754631	116754951
ENSE00000785007	116760402	116760632
ENSE00000785008	116764484	116764606
ENSE00001141790	116768464	116769229
ENSE00001450130	116754430	116754553

Expression profiles

Bgee: expression breadth ubiquitous, 206 present calls, max score 98.58.

FANTOM5 (CAGE): breadth broad, TPM avg 15.3717 / max 991.0433, expressed in 253 samples.

Highest expression (Bgee): granulocyte, thymus, lymph node, male germ line stem cell (sensu Vertebrata) in testis, vermiform appendix.

Genetic regulation across tissues (GTEx eQTL / sQTL)

CD2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 3 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

3 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Skin Sun Exposed Lower leg	eqtl	6.5e-03	-0.30	1:116195123:G:A
Esophagus Mucosa	eqtl	2.5e-02	+0.08	1:116755162:A:G
Spleen	eqtl	4.8e-02	-0.40	1:116154490:C:T

FANTOM5 promoters

3 alternative TSS:

Promoter ID	TPM avg	Samples expressed
4854	15.0074	250
4856	0.2308	60
4855	0.1335	56

Top tissues by expression

showing 100 of 285 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	98.58	gold quality
thymus	UBERON:0002370	96.18	gold quality
lymph node	UBERON:0000029	95.41	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	94.79	gold quality
vermiform appendix	UBERON:0001154	94.51	gold quality
blood	UBERON:0000178	94.40	gold quality
epithelium of nasopharynx	UBERON:0001951	93.91	gold quality
superficial temporal artery	UBERON:0001614	92.94	gold quality
spleen	UBERON:0002106	90.48	gold quality
ileal mucosa	UBERON:0000331	90.47	gold quality
caecum	UBERON:0001153	89.05	gold quality
jejunal mucosa	UBERON:0000399	88.15	gold quality
gall bladder	UBERON:0002110	86.31	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.18	gold quality
decidua	UBERON:0002450	85.69	gold quality
palpebral conjunctiva	UBERON:0001812	85.28	gold quality
rectum	UBERON:0001052	84.90	gold quality
tonsil	UBERON:0002372	84.41	gold quality
type B pancreatic cell	CL:0000169	84.38	gold quality
small intestine Peyer’s patch	UBERON:0003454	84.23	gold quality
mucosa of paranasal sinus	UBERON:0005030	84.10	silver quality
olfactory bulb	UBERON:0002264	84.06	gold quality
mucosa of urinary bladder	UBERON:0001259	83.52	gold quality
cervix squamous epithelium	UBERON:0006922	83.25	silver quality
small intestine	UBERON:0002108	83.13	gold quality
colonic epithelium	UBERON:0000397	82.61	gold quality
bone marrow	UBERON:0002371	82.26	gold quality
cervix epithelium	UBERON:0004801	82.00	gold quality
mucosa of transverse colon	UBERON:0004991	81.70	gold quality
duodenum	UBERON:0002114	81.58	gold quality
bone marrow cell	CL:0002092	80.94	gold quality
left ventricle myocardium	UBERON:0006566	80.38	gold quality
hair follicle	UBERON:0002073	80.23	gold quality
nasal cavity epithelium	UBERON:0005384	79.82	gold quality
oral cavity	UBERON:0000167	78.38	gold quality
mammary duct	UBERON:0001765	77.83	gold quality
esophagus squamous epithelium	UBERON:0006920	77.64	gold quality
cardiac muscle of right atrium	UBERON:0003379	77.38	silver quality
epithelium of mammary gland	UBERON:0003244	77.20	gold quality
lung	UBERON:0002048	76.98	gold quality
squamous epithelium	UBERON:0006914	76.97	gold quality
trabecular bone tissue	UBERON:0002483	76.96	gold quality
upper lobe of left lung	UBERON:0008952	76.64	gold quality
jejunum	UBERON:0002115	76.55	gold quality
right uterine tube	UBERON:0001302	76.51	gold quality
colonic mucosa	UBERON:0000317	76.27	gold quality
upper lobe of lung	UBERON:0008948	76.13	gold quality
smooth muscle tissue	UBERON:0001135	76.00	gold quality
amniotic fluid	UBERON:0000173	75.99	gold quality
germinal epithelium of ovary	UBERON:0001304	75.85	gold quality
right coronary artery	UBERON:0001625	75.64	gold quality
parietal pleura	UBERON:0002400	75.53	gold quality
epithelium of esophagus	UBERON:0001976	75.39	gold quality
mucosa of sigmoid colon	UBERON:0004993	75.32	gold quality
pleura	UBERON:0000977	75.07	gold quality
nasal cavity mucosa	UBERON:0001826	74.47	gold quality
right lung	UBERON:0002167	74.14	gold quality
CA1 field of hippocampus	UBERON:0003881	74.11	gold quality
diaphragm	UBERON:0001103	73.94	gold quality
body of stomach	UBERON:0001161	73.87	gold quality
urinary bladder	UBERON:0001255	73.77	gold quality
skin of hip	UBERON:0001554	73.57	gold quality
lower lobe of lung	UBERON:0008949	73.51	silver quality
visceral pleura	UBERON:0002401	73.28	gold quality
intestine	UBERON:0000160	72.98	gold quality
fundus of stomach	UBERON:0001160	72.92	gold quality
gingiva	UBERON:0001828	72.74	silver quality
oviduct epithelium	UBERON:0004804	72.74	silver quality
mammalian vulva	UBERON:0000997	72.64	gold quality
stomach	UBERON:0000945	72.46	gold quality
vastus lateralis	UBERON:0001379	72.40	gold quality
leukocyte	CL:0000738	72.39	gold quality
transverse colon	UBERON:0001157	72.37	gold quality
quadriceps femoris	UBERON:0001377	72.10	gold quality
omental fat pad	UBERON:0010414	71.93	gold quality
peritoneum	UBERON:0002358	71.89	gold quality
epithelium of bronchus	UBERON:0002031	71.87	gold quality
mammary gland	UBERON:0001911	71.85	gold quality
bronchus	UBERON:0002185	71.84	gold quality
thoracic mammary gland	UBERON:0005200	71.82	gold quality
fallopian tube	UBERON:0003889	71.78	gold quality
adipose tissue of abdominal region	UBERON:0007808	71.64	gold quality
gingival epithelium	UBERON:0001949	71.36	gold quality
pylorus	UBERON:0001166	71.17	gold quality
uterine cervix	UBERON:0000002	71.06	gold quality
esophagus mucosa	UBERON:0002469	70.23	gold quality
large intestine	UBERON:0000059	70.04	gold quality
mononuclear cell	CL:0000842	69.88	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	69.69	gold quality
endometrium	UBERON:0001295	69.59	gold quality
left uterine tube	UBERON:0001303	69.57	gold quality
colon	UBERON:0001155	69.52	gold quality
triceps brachii	UBERON:0001509	69.42	gold quality
gluteal muscle	UBERON:0002000	69.30	gold quality
bronchial epithelial cell	CL:0002328	69.14	gold quality
monocyte	CL:0000576	68.98	gold quality
periodontal ligament	UBERON:0008266	68.95	silver quality
mucosa of stomach	UBERON:0001199	68.93	gold quality
right lobe of liver	UBERON:0001114	68.92	gold quality
upper leg skin	UBERON:0004262	68.44	gold quality

Single-cell (SCXA)

Detected in 30 experiment(s), a significant marker in 23.

Experiment	Marker?	Max mean expression
E-MTAB-6505	yes	3052.54
E-CURD-97	yes	2337.74
E-GEOD-139324	yes	1676.04
E-MTAB-8410	yes	1507.01
E-HCAD-36	yes	920.44
E-HCAD-15	yes	868.34
E-MTAB-10553	yes	825.29
E-CURD-88	yes	802.09
E-MTAB-9221	yes	773.22
E-MTAB-10287	yes	681.85
E-CURD-122	yes	666.18
E-HCAD-1	yes	651.91
E-CURD-46	yes	630.77
E-GEOD-75688	yes	614.70
E-MTAB-8142	yes	93.56

HPA expression

RNA tissue specificity: Tissue enriched

showing 60 of 74 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Thymus	tissue	232.5
Lymph node	tissue	111.9	medium
Tonsil	tissue	74.1	medium
Appendix	tissue	48.4	medium
Spleen	tissue	41.5	high
Small intestine	tissue	26.8	not detected
Stomach 1	tissue	22.7	not detected
Lung	tissue	19.8	not detected
Urinary bladder	tissue	19.5	not detected
Duodenum	tissue	16.2	not detected
Gallbladder	tissue	15.8	not detected
Rectum	tissue	15.0	not detected
Colon	tissue	13.0	not detected
Bone marrow	tissue	10.7	not detected
Salivary gland	tissue	8.1	not detected
Esophagus	tissue	7.9	not detected
Liver	tissue	7.3	not detected
Breast	tissue	7.1	not detected
Spinal cord	tissue	6.6
Cervix	tissue	5.5	not detected
Periaqueductal gray	tissue	5.0
Prostate	tissue	4.8	not detected
Substantia nigra	tissue	4.6
Hypothalamus	tissue	4.5
Adrenal gland	tissue	4.4	not detected
Adipose tissue	tissue	4.3	not detected
Medulla oblongata	tissue	4.3
Smooth muscle	tissue	4.1	not detected
Fallopian tube	tissue	3.9	not detected
Pons	tissue	3.7
Endometrium 1	tissue	3.5	not detected
Skin 1	tissue	3.3	low
Vagina	tissue	3.2	not detected
Septum	tissue	3.2
Pancreas	tissue	2.8	not detected
Thyroid gland	tissue	2.8	not detected
Epididymis	tissue	2.6	not detected
Heart muscle	tissue	2.4	not detected
Kidney	tissue	2.4	not detected
Superior colliculi	tissue	2.3
Seminal vesicle	tissue	2.1	not detected
Thalamus	tissue	2.1
Olfactory bulb	tissue	2.0
Midbrain	tissue	1.9
Testis	tissue	1.7	low
Ovary	tissue	1.7	not detected
Corpus callosum	tissue	1.7
Tongue	tissue	1.6
Skeletal muscle	tissue	1.3	not detected
Hippocampal formation	tissue	1.1
Choroid plexus	tissue	1.0
Placenta	tissue	1.0	not detected
Ventral forebrain	tissue	1.0
Parathyroid gland	tissue	0.8	not detected
Entorhinal cortex	tissue	0.8
Pituitary gland	tissue	0.7
Basal ganglia	tissue	0.7	not detected
Putamen	tissue	0.7
Amygdala	tissue	0.7
Cerebral cortex	tissue	0.6	not detected

Brain sub-regions (HPA Brain Atlas): detected in 180; highest nTPM — Dorsal spinal cord (6.6), Ventral spinal cord (5.0), Blood vessel (2.9), Nucleus gracilis (2.3), White matter (1.7).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AHR, BATF, DNMT1, GATA4, GLI2, MAF, NFKB1, NFKB2, NR1H3, RUNX1, TCFL5, TP53, TXK, USF1, USF2

miRNA regulators (miRDB)

Targeting CD2 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

17 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-208A-5P	99.42	70.83	1913
HSA-MIR-208B-5P	99.42	70.83	1952
HSA-MIR-508-5P	99.41	64.25	1248
HSA-MIR-4685-5P	99.25	65.99	1563
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-4705	99.10	69.10	1091
HSA-MIR-3675-3P	99.09	67.70	968
HSA-MIR-4478	99.07	65.16	2320
HSA-MIR-6769B-5P	98.73	64.91	1092
HSA-MIR-216B-3P	98.55	67.19	1223
HSA-MIR-6792-5P	98.39	68.16	1330
HSA-MIR-3929	98.32	65.58	1026
HSA-MIR-6735-5P	98.24	65.36	1488
HSA-MIR-216B-5P	97.16	66.76	1126
HSA-MIR-541-3P	96.07	66.11	1271
HSA-MIR-654-5P	96.07	66.18	1280

Functional genomics

gnomAD constraint: pLI 2.63e-05, LOEUF 1.14, missense Z 0.272 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000369478 — one region, missense o/e 1.00.

Literature-anchored findings (GeneRIF, showing 40)

• CD2-CD58 binding site (PMID:11575926)
• PTEN expression was up-regulated on RNA and protein level in freshly isolated human CD4(+) T cells following stimulation with CD28 or CD2. (PMID:11932928)
• molecules redistribute to the uropod during T cell scanning (PMID:12032326)
• Structural and functional studies of the extracellular domains of CD2 and CD58 and their complex. Review. (PMID:12369898)
• CD2BP2 is the ligand of the membrane-proximal proline-rich tandem repeat of CD2 in detergent-soluble membrane compartments, but is replaced by Fyn SH3 after CD2 is translocated into lipid rafts upon CD2 ectodomain clustering. (PMID:12426371)
• PSTPIP1 acts downstream of CD2/CD2AP to link CD2 engagement to the WASp-evoked actin polymerization required for synapse formation and T cell activation. (PMID:12530983)
• This T cell surface antigen is linked to the actin-capping protein CAPZ via CMS and CIN85. (PMID:12690097)
• another role of the CD2-CD58 pathway that allows nonimmune and immune cells to interact directly with dendritic cells and initiate innate and adaptive immune responses. (PMID:12714509)
• CD2 mediates activation of the IFN-gamma intronic STAT binding region in mucosal T cells. (PMID:12731040)
• CD2 mediates activation of a distal -3.6-kilobase STAT5 binding region of the interferon-gamma promoter. (PMID:15528362)
• CD48 is a CD2 and CD244 (2B4)-binding protein (PMID:16803907)
• We use this analysis to determine that the 2D Kd for CD2-CD58 is 5.4-7.6 molecules/microm2. 2D Kd analysis provides a general and quantitative measure of the mechanisms regulating cell-cell adhesion. (PMID:17085486)
• T cell activation causes the CD58-bound CD2 to be recognized and immobilized at sites of cell-cell contact, thereby strengthening T cell-APC adhesion (PMID:17168569)
• results showed that the expression of CD2 significantly increased with the severity of chronic HBV infection, which suggested that CD2 might contribute to the hepatocyte damage in chronic HBV infection (PMID:18318997)
• Data suggest that detection of CD2 or CD13 expression in chronic lymphocytic leukemia (CLL) suggests familial CLL, and that CD38 expression does not carry the negative prognosis observed in sporadic CLL. (PMID:18431797)
• the synergistic synthesis of IL-8 occurs when lymphocytes are stimulated through the CD2 pathway by CD58 on HT-29 cells, resulting in TNF-alpha release that, in turn, augments IL-8 synthesis and CD58 expression by the HT-29 cells (PMID:19109405)
• during clinical remission, increases in CD58 expression, mediated by the protective allele, up-regulate the expression of FoxP3 through engagement of the CD58 receptor, CD2, leading to the enhanced function of TREG cells that are defective in MS (PMID:19237575)
• CD2 functions as the master switch recruiting CD48 and Lck (PMID:19494291)
• LFA-1 and CD2 synergize for the Erk1/2 activation in the Natural Killer (NK) cell immunological synapse (PMID:19502238)
• CD244 inhibition and activation depends on CD2 and phospholipase C-gamma1 (PMID:19586919)
• Genetic variants at CD2 are associated with rheumatoid arthritis risk (PMID:19898481)
• analysis of the importance of homotypic NK-to-NK cell cross-talk through 2B4/CD48 and CD2/CD58 pairs and further present their differential and overlapping roles in human NK cells (PMID:20813844)
• When isolated from multiple sclerosis patients, both nonmature and effector subsets of memory CD127(low) regulatory T cells exhibit kinetically distinct defects in suppression that are evident with CD2 pathway costimulation. (PMID:21300823)
• CD2 signals more strongly to S6-ribosomal protein, whereas CD28 costimulation specifically induces signaling necessary for proper NF-kappaB activation. (PMID:22013130)
• CD2-mediated priming of resting natural killer (NK) cells is unaffected by their degree of functional maturation. (PMID:22084431)
• CD2 expression does not contribute to improve the diagnosis of systemic mastocytosis when compared with aberrant CD25 expression alone. (PMID:22222639)
• Aberrant CD2 expression appears to further determine a shorter progression free survival (PMID:22634534)
• CD2-CD58/48 receptor-ligand interaction promotes and is required for nanotube formation in human natural killer cells. (PMID:23112830)
• Altogether, these results show that a high CD2 expression level is a hallmark of latently infected resting memory CD4(+) T cells in vivo. (PMID:23760244)
• ERGdel may be a pure surrogate of CD2-positivity–which has been suggested to be a good prognositc marker in childhood ALL (PMID:24072102)
• Both the mRNA expression levels and protein expression levels of HSP27 were increased in astrocytes from POAG patients compared with those from normal control, suggesting that mutation in CD2 might pose a risk for POAG in Chinese population. (PMID:24597656)
• Although sMCs displayed immunoreactivity for one of the neoplastic antigens in the majority of SM patients, the aberrant CD2 and/or CD25 expression on sMCs is not as indicative of SM as the BMMC immunophenotype. (PMID:25402852)
• the fundamental mechanism of glycosylation of human CD2 is to promote CD2-CD58 binding by conformational adjustment of CD2 (PMID:25984915)
• CD58/CD2 is the primary costimulatory pathway in human CD28-CD8+ T cells. (PMID:26041540)
• These results reveal an unexpected redundancy in the human NK cell response to human cytomegalovirus and suggest that CD2 provides “signal 2” in antibody-driven adaptive NK cell responses. (PMID:27117418)
• Establish CD2 as a new susceptibility factor for systemic sclerosis in a European Caucasian population. (PMID:27385538)
• A new prognostic model for HR-/HER2+ breast cancer based on the expression of MMP11 and CD2 was developed and the distant metastasis-free survival for patients in the high-risk group according to our model was significantly lower than that for those in the low-risk group. (PMID:28409241)
• Keratinocytes costimulate naive human T cells via CD2: a potential target to prevent the development of proinflammatory Th1 cells in the skin. (PMID:31324882)
• Phosphoproteomics of CD2 signaling reveals AMPK-dependent regulation of lytic granule polarization in cytotoxic T cells. (PMID:32398348)
• CD2 and CD7 are sensitive flow cytometry screening markers for T-lineage acute leukemia(s): a study of 465 acute leukemia cases. (PMID:34019867)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Cd2	ENSMUSG00000027863
rattus_norvegicus	Cd2	ENSRNOG00000015821

Paralogs (9): SLAMF7 (ENSG00000026751), CD84 (ENSG00000066294), SLAMF1 (ENSG00000117090), CD48 (ENSG00000117091), CD244 (ENSG00000122223), LY9 (ENSG00000122224), SLAMF8 (ENSG00000158714), SLAMF9 (ENSG00000162723), SLAMF6 (ENSG00000162739)

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Macaca fascicularis	Q6SZ61	94.6%	Diamond
Equus caballus	P37998	58.6%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
PTGFRN	protein-coding	5738
CD101	protein-coding	9398
LINC02868	ncRNA	388667
MIR320B1	ncRNA	100302117

Protein

Protein identifiers

T-cell surface antigen CD2 — P06729 (reviewed: P06729)

Alternative names: Erythrocyte receptor, LFA-2, LFA-3 receptor, Rosette receptor, T-cell surface antigen T11/Leu-5

All UniProt accessions (4): B4E0G3, P06729, Q53F96, Q5JVN7

UniProt curated annotations — full annotation on UniProt →

Function. CD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T-cells, the cytoplasmic domain is implicated in the signaling function.

Subunit / interactions. Interacts with CD48. Interacts with CD58 (LFA-3). Interacts with CD2AP. Interacts with PSTPIP1. Interacts with FCGR3A; this interaction modulates NK cell activation and cytotoxicity.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in natural killer cells (at protein level).

RefSeq proteins (2): NP_001315538, NP_001758* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008424	Ig_C2-set	Domain
IPR013106	Ig_V-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR015631	CD2/SLAM_rcpt	Family
IPR015632	CD2	Family
IPR036179	Ig-like_dom_sf	Homologous_superfamily

Pfam: PF05790, PF07686

UniProt features (52 total): strand 16, helix 7, mutagenesis site 4, compositionally biased region 3, glycosylation site 3, sequence variant 3, region of interest 3, disulfide bond 2, topological domain 2, sequence conflict 2, turn 2, domain 2, signal peptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

7 structures by resolution:

PDB	Title	Method	Resolution (Å)
2J6O	ATYPICAL POLYPROLINE RECOGNITION BY THE CMS N-TERMINAL SH3 DOMAIN. CMS:CD2 HETEROTRIMER	X-RAY DIFFRACTION	2.23
1HNF	CRYSTAL STRUCTURE OF THE EXTRACELLULAR REGION OF THE HUMAN CELL ADHESION MOLECULE CD2 AT …	X-RAY DIFFRACTION	2.5
2J7I	ATYPICAL POLYPROLINE RECOGNITION BY THE CMS N-TERMINAL SH3 DOMAIN. CMS:CD2 HETERODIMER	X-RAY DIFFRACTION	2.9
1QA9	Structure of a Heterophilic Adhesion Complex Between the Human CD2 and CD58(LFA-3) …	X-RAY DIFFRACTION	3.2
1CDB	STRUCTURE OF THE GLYCOSYLATED ADHESION DOMAIN OF HUMAN T LYMPHOCYTE GLYCOPROTEIN CD2	SOLUTION NMR
1GYA	N-GLYCAN AND POLYPEPTIDE NMR SOLUTION STRUCTURES OF THE ADHESION DOMAIN OF HUMAN CD2	SOLUTION NMR
1L2Z	CD2BP2-GYF domain in complex with proline-rich CD2 tail segment peptide	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P06729-F1	78.25	0.53

Human Protein Atlas

Protein class: CD markers, Predicted membrane proteins, Predicted intracellular proteins, FDA approved drug targets, Biotech drugs

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): plasma membrane; golgi apparatus; nucleoplasm

Antibody reliability (HPA): IH enhanced · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2)

Type	Positions
Disulfide bond	139–203, 146–186

Glycosylation sites (3)

Type	Positions
N-linked (glcnac…) asparagine	89, 141, 150

Mutagenesis-validated functional residues (4)

Position	Phenotype
67	loss of cd58 binding.
70	loss of cd58 binding.
110	loss of cd58 and cd59 binding.
111	loss of cd58 and cd59 binding.

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 2; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

2 pathways:

ID	Pathway	Evidence
R-HSA-202733	Cell surface interactions at the vascular wall	curated
R-HSA-109582	Hemostasis	—

MSigDB gene sets: 319 (showing top): FERRANDO_TAL1_NEIGHBORS, GOBP_REGULATION_OF_CELL_ACTIVATION, VERHAAK_AML_WITH_NPM1_MUTATED_DN, WALLACE_PROSTATE_CANCER_RACE_UP, MODULE_169, GOBP_POSITIVE_REGULATION_OF_INTERLEUKIN_8_PRODUCTION, MODULE_45, MODULE_64, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP, GOCC_CELL_SURFACE, GOBP_LEUKOCYTE_MEDIATED_CYTOTOXICITY, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, DARWICHE_PAPILLOMA_PROGRESSION_RISK, GOBP_MEMBRANE_RAFT_ORGANIZATION

GO Biological Process (15): membrane raft polarization (GO:0001766), apoptotic process (GO:0006915), immune response (GO:0006955), cell surface receptor signaling pathway (GO:0007166), natural killer cell activation (GO:0030101), positive regulation of myeloid dendritic cell activation (GO:0030887), positive regulation of type II interferon production (GO:0032729), positive regulation of interleukin-8 production (GO:0032757), positive regulation of tumor necrosis factor production (GO:0032760), heterotypic cell-cell adhesion (GO:0034113), T cell activation (GO:0042110), natural killer cell mediated cytotoxicity (GO:0042267), regulation of T cell differentiation (GO:0045580), cell-cell adhesion (GO:0098609), cell adhesion (GO:0007155)

GO Molecular Function (6): signaling receptor binding (GO:0005102), receptor tyrosine kinase binding (GO:0030971), signaling receptor activity (GO:0038023), identical protein binding (GO:0042802), protein binding (GO:0005515), protein kinase binding (GO:0019901)

GO Cellular Component (8): extracellular region (GO:0005576), plasma membrane (GO:0005886), cell-cell junction (GO:0005911), external side of plasma membrane (GO:0009897), cytoplasmic side of plasma membrane (GO:0009898), cell surface (GO:0009986), protein-containing complex (GO:0032991), membrane (GO:0016020)

Reactome top-level categories

1 top-level categories:

Category	Pathways
Hemostasis	1

GO top-level categories

42 GO namespaces:

Category	Terms
cellular anatomical structure	3
lymphocyte activation	2
positive regulation of cytokine production	2
protein binding	2
plasma membrane	2
membrane raft distribution	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
immune system process	1
response to stimulus	1
signal transduction	1
myeloid dendritic cell activation	1
positive regulation of leukocyte activation	1
regulation of myeloid dendritic cell activation	1
type II interferon production	1
regulation of type II interferon production	1
interleukin-8 production	1
regulation of interleukin-8 production	1
tumor necrosis factor production	1
regulation of tumor necrosis factor production	1
positive regulation of tumor necrosis factor superfamily cytokine production	1
cell-cell adhesion	1
leukocyte mediated cytotoxicity	1
natural killer cell mediated immunity	1
T cell differentiation	1
regulation of lymphocyte differentiation	1
regulation of T cell activation	1
cell adhesion	1
cellular process	1
signaling receptor binding	1
protein tyrosine kinase binding	1
molecular transducer activity	1
binding	1
kinase binding	1
membrane	1
cell periphery	1
anchoring junction	1
cell surface	1
side of membrane	1
cytoplasmic side of membrane	1
cellular_component	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 10 of 29 annotations. The rest are phylogenetic / computational / electronic (IEA).

10 experimentally-supported GO terms:

GO term	NS	Evidence
heterotypic cell-cell adhesion	BP	direct assay
natural killer cell activation	BP	direct assay
natural killer cell mediated cytotoxicity	BP	direct assay
positive regulation of interleukin-8 production	BP	mutant phenotype
positive regulation of tumor necrosis factor production	BP	direct assay
positive regulation of type II interferon production	BP	direct assay
cell surface	CC	direct assay
external side of plasma membrane	CC	direct assay
plasma membrane	CC	direct assay
signaling receptor binding	MF	physical interaction

Protein interactions and networks

STRING

showing 15 of 2,308 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CD2	CD58	P19256	964
CD2	CD4	P01730	908
CD2	CD8A	P01732	900
CD2	CD7	P09564	884
CD2	CD5	P06127	881
CD2	CD48	P09326	845
CD2	CD28	P10747	839
CD2	CD1C	P29017	810
CD2	NCAM1	P13591	800
CD2	ITGAL	P20701	785
CD2	CD19	P15391	771
CD2	IL3RA	P26951	759
CD2	TNFRSF8	P28908	758
CD2	MME	P08473	751
CD2	SLAMF1	Q13291	751

IntAct

Human interaction partners of CD2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

11 partners by confidence:

Partner	Interaction type	MIscore	Records
CD2BP2	direct interaction	0.930	14
CD2AP	physical association	0.800	6
PSTPIP1	physical association	0.740	6
CD58	physical association	0.710	4
SH3KBP1	direct interaction	0.620	3
FYN	phosphorylation reaction	0.570	3
EP300	physical association	0.370	1
LYAR	physical association	0.370	1
LCK	phosphorylation reaction	0.310	1
CKS1B	proximity	0.270	1
DNAJC5	proximity	0.270	1

BioGRID (36 interactions; top human partners by supporting records): CD2AP (Co-crystal Structure; 6 records), SH3KBP1 (Co-crystal Structure; 6 records), CD2BP2 (Two-hybrid; 4 records), CD58 (Co-crystal Structure; 2 records), LCK (Affinity Capture-Western; 2 records), PSTPIP1 (Two-hybrid; 2 records), CD48 (Reconstituted Complex), CD5 (Affinity Capture-Western), CD53 (Affinity Capture-Western), CHD3 (Cross-Linking-MS (XL-MS)), DNAJC5 (FRET), FYN (Reconstituted Complex), ITK (Affinity Capture-Western), LGALS1 (Affinity Capture-Western), LINC00311 (Two-hybrid)

Protein complexes (CORUM) (1)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

1 complexes by size:

Complex	Subunits	Members
★ CD2-CD247-FCGR3A complex	3	CD2, CD247, FCGR3A

Ligand–receptor pairs (CellPhoneDB) (1)

Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.

1 ligand–receptor pairs:

Partner	This gene’s role	Signaling class
CD58	receptor

Disease & clinical

Genetic variants

Variant evidence for CD2: 67 ClinVar records (0 pathogenic / likely pathogenic); 9 GWAS associations.

ClinVar

67 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	56
Likely benign	8
Benign	1

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 34 predictions of 270):

Position(s)	Effect	Δscore	Sites
1:116754952–116754953	donor_loss	0.9900	5
1:116764482–116764483	acceptor_loss	0.9900	6
1:116764607–116764608	donor_loss	0.9900	5
1:116764481	acceptor_loss	0.9800
1:116764608	donor_loss	0.9800
1:116768462–116768463	acceptor_loss	0.9800	4
1:116760400–116760401	acceptor_loss	0.9700	6
1:116768461–116768463	acceptor_loss	0.9700	3
1:116760112	donor_gain	0.9500
1:116764609	donor_loss	0.9500	2

AlphaMissense

415 missense substitutions predicted likely pathogenic (of 2,322 scored), across 127 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
N190	8	0.956	0.993
C146	7	0.993	0.997
C186	7	0.989	0.998
W59	7	0.987	0.999
C139	7	0.976	0.987
C203	7	0.958	0.981
W176	7	0.889	0.991
F184	7	0.885	0.984
F48	7	0.837	0.954
W137	7	0.830	0.975
D56	7	0.732	0.877
D40	7	0.723	0.855
P133	6	0.967	0.993
P329	6	0.914	0.950
S193	6	0.909	0.987
P331	6	0.862	0.922
D111	6	0.804	0.902
Y105	5	0.960	0.993
G114	5	0.939	0.979
G90	5	0.927	0.983

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

2 prognostic cancer types:

Cancer	Prognostic	p-value
Skin Cutaneous Melanoma (TCGA)	favorable	0.000187
Head and Neck Squamous Cell Carcinoma (TCGA)	favorable	0.000395

Disease associations

OMIM: gene MIM:186990 | disease phenotypes:

GWAS associations

9 associations:

Study	Trait	p-value
GCST002318_92	Rheumatoid arthritis	8e-10
GCST007932_37	Medication use (thyroid preparations)	4e-8
GCST006959_160	Rheumatoid arthritis	5e-8
GCST010273_1	Gout (normal type)	5e-8
GCST006048_39	Rheumatoid arthritis (ACPA-positive)	9e-8
GCST006959_22	Rheumatoid arthritis	9e-7
GCST009597_306	Multiple sclerosis	5e-6
GCST005568_52	Rheumatoid arthritis (ACPA-positive)	6e-6
GCST008158_92	Body mass index	7e-6

EFO canonical traits (from GWAS)

2 canonical traits:

EFO ID	Trait name
EFO:0009933	Thyroid preparation use measurement
EFO:0004340	body mass index

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2040 (SINGLE PROTEIN), CHEMBL3885600 (PROTEIN-PROTEIN INTERACTION)

Drugs by curated mechanism of action (ChEMBL)

Drugs whose curated ChEMBL mechanism of action targets the CD2 protein itself — single-protein targets only (drugs acting on a protein family or complex that merely includes it are excluded). Includes antibodies and oligonucleotides that bioactivity screening does not capture.

2 curated-mechanism drugs:

Drug	Modality	Max phase
ALEFACEPT	Protein	4
SIPLIZUMAB	Antibody	2

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — CD molecules

Binding affinities (BindingDB)

2 measured of 2 human assays (2 total across all organisms); most potent 2 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL2153727	IC50	9.4 nM
CHEMBL2153728	IC50	25.7 nM

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.16	IC50	6.9	nM	CHEMBL2153727
8.03	IC50	9.4	nM	CHEMBL2153727
7.96	IC50	11.1	nM	CHEMBL2153728
7.59	IC50	25.7	nM	CHEMBL2153728

PubChem BioAssay actives

4 with measured affinity, of 18 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(3R,9S,12S,15S,18S,21S,24S,27S,30S,33S)-21-(4-aminobutyl)-15,24-bis[(2S)-butan-2-yl]-9,27-bis(carboxymethyl)-18-(hydroxymethyl)-12-[(4-hydroxyphenyl)methyl]-2,8,11,14,17,20,23,26,29,32-decaoxo-1,7,10,13,16,19,22,25,28,31-decazatricyclo[31.3.0.03,7]hexatriacontan-30-yl]acetic acid	689909: Inhibition of CD2-CD58 protein-protein interaction assessed as inhibition of cell adhesion between CD58 expressing human Caco2 cells and CD2 expressing human Jurkat cells by BCECF-AM fluorescent dye based fluorimetric assay	ic50	0.0069	uM
2-[(13S,16S,19S,22S,25S,28S)-19-(4-aminobutyl)-22-[(2S)-butan-2-yl]-13,16-bis(carboxymethyl)-25-[(4-hydroxyphenyl)methyl]-12,15,18,21,24,27,30-heptaoxo-2-oxa-11,14,17,20,23,26,29-heptazatetracyclo[31.4.0.03,8.04,37]heptatriaconta-1(33),3(8),4,6,34,36-hexaen-28-yl]acetic acid	689909: Inhibition of CD2-CD58 protein-protein interaction assessed as inhibition of cell adhesion between CD58 expressing human Caco2 cells and CD2 expressing human Jurkat cells by BCECF-AM fluorescent dye based fluorimetric assay	ic50	0.0111	uM

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Acetaminophen	decreases expression, increases expression, affects cotreatment	2
Arsenic	increases expression, increases methylation, increases abundance	2
triphenyl phosphate	affects expression	1
sodium arsenate	increases abundance, increases expression	1
tetrabromobisphenol A	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
(+)-JQ1 compound	decreases expression	1
Temozolomide	decreases expression	1
Amphotericin B	increases expression	1
Benzo(a)pyrene	increases methylation	1
Dietary Carbohydrates	affects cotreatment, decreases expression	1
Formaldehyde	increases expression	1
Methotrexate	decreases expression	1
Nickel	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Isotretinoin	increases expression	1
Tacrolimus	decreases reaction, increases expression	1
Aflatoxin B1	increases methylation	1
Sodium Selenite	increases expression	1
Antirheumatic Agents	decreases expression	1

ChEMBL screening assays

5 unique, capped per target: 5 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1023747	Binding	Inhibition of CD2-CD58 interaction assessed as inhibition of CD2 expressing human Jurkat T cell adhesion to CD58 expressing human Caco-2 cells at 90 uM after 45 mins by microplate fluorescence analysis	Design of beta-hairpin peptides for modulation of cell adhesion by beta-turn constraint. — *J Med Chem*

Cellosaurus cell lines

8 cell lines: 7 cancer cell line, 1 factor-dependent cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1D50	2C4 [Human fibrosarcoma]	Cancer cell line	Male
CVCL_1D51	2C4 gamma1A/JAK2	Cancer cell line	Male
CVCL_A8X0	BL2-5-8	Factor-dependent cell line
CVCL_C0D3	2C4 gamma1A	Cancer cell line	Male
CVCL_C0D4	2C4 gamma2A	Cancer cell line	Male
CVCL_C0D5	2C4 gamma2A/JAK2	Cancer cell line	Male
CVCL_E8IK	Jurkat-NFAT-Luc2-CD2-KO-1B4	Cancer cell line	Male
CVCL_E8IL	Jurkat-NFAT-Luc2-CD2-KO-2A2	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT00029224	Phase 4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	Phase 4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	Phase 4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	Phase 4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	Phase 4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	Phase 4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	Phase 4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	Phase 4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	Phase 4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	Phase 4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	Phase 4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	Phase 4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	Phase 4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	Phase 4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	Phase 4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	Phase 4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	Phase 4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	Phase 4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	Phase 4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	Phase 4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	Phase 4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	Phase 4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	Phase 4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	Phase 4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	Phase 4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	Phase 4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	Phase 4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	Phase 4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	Phase 4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	Phase 4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	Phase 4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	Phase 4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	Phase 4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	Phase 4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	Phase 4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	Phase 4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	Phase 4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	Phase 4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	Phase 4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	Phase 4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
NCT01673984	Phase 4	TERMINATED	GP Extended Action Triptorelin
NCT01753297	Phase 4	COMPLETED	A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
NCT01794793	Phase 4	COMPLETED	Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
NCT01950871	Phase 4	TERMINATED	Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning
NCT01995513	Phase 4	COMPLETED	Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
NCT02102646	Phase 4	COMPLETED	MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism
NCT02116582	Phase 4	COMPLETED	A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
NCT02149628	Phase 4	COMPLETED	The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide
NCT02405858	Phase 4	COMPLETED	A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
NCT02441517	Phase 4	TERMINATED	A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
NCT02441894	Phase 4	COMPLETED	Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer
NCT02475057	Phase 4	COMPLETED	Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists
NCT02511665	Phase 4	UNKNOWN	Metformin And Longevity
NCT02651948	Phase 4	COMPLETED	Transperineal, MRI-guided, Prostate Biopsy
NCT02721433	Phase 4	COMPLETED	4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
NCT02726009	Phase 4	COMPLETED	A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
NCT02749825	Phase 4	TERMINATED	Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
NCT02757365	Phase 4	UNKNOWN	Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer
NCT02773251	Phase 4	COMPLETED	The Effect of Guardix-solution for the Prevention of Postoperative Intestinal Adhesion and Intestinal Obstruction After Laparoscopic Pelvic Cavity Surgery
NCT02812186	Phase 4	COMPLETED	Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for CD2 across ~30M SureChEMBL compounds — explore on Sugi Predict.